Predictive Value of Autoantibodies in Clinically Suspect Arthralgia and Risk for RA
The presence of the certain autoantibodies accurately predicts a person’s risk for progression from clinically suspect arthralgia to rheumatoid arthritis.
The presence of the certain autoantibodies accurately predicts a person’s risk for progression from clinically suspect arthralgia to rheumatoid arthritis.
Pooled results examine the incidence of antidrug antibody development after both intravenous and subcutaneously administered tocilizumab for rheumatoid arthritis.
Antibody concentrations against antigen epitopes of the oral pathogen P gingivalis appear to increase prior to the onset of RA symptoms, suggesting that P gingivalis may be associated with RA pathogenesis.
At 24 months, rates of vertebral fractures were significantly lower in the romosozumab group.
Low IgG and B cell counts were associated with infection and vaccine response among patients with systemic vasculitis in stable remission.
Amgen and UCB announced the submission of a Biologics License Application (BLA) to the Food and Drug Administration (FDA) for romosozumab for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.
Features distinguishing SLE-AIH from primary AIH were examined by researchers in an effort to improve treatment responses and prognosis
Persistent lupus anticoagulant positivity in patients with antineutrophil cytoplasmic antibody-associated vasculitis is associated with higher Vasculitis Damage Index scores.
Serum immunoglobulin levels against the periodontal antigen Porphyromonas gingivalis peptidylarginine deiminase appear to correlate with the clinical responses to bDMARD therapy in RA
The predictive value for future need for immunosuppression of anti-smith antibodies found on biopsy-proven lupus nephritis was evaluated in a retrospective analysis